N/A
Completed N=83
Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients
Source: ClinicalTrials.gov NCT01375127 ↗Enrolled (actual)
83
Serious AEs
0.0%
Results posted
Aug 2013
Primary outcomePrimary: Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD) — 0; 0; 0; 0 participants
Summary
This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD) |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Number of Participants With Central Nervous System (CNS) Infection |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Number of Participants With Graft Failure |
0; 0; 2; 3; 0; 0 | — |
| PRIMARY Number of Participants Who Died |
0; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects have discontinued tofacitinib prior to the planned treatment duration in 2 completed Phase 2 studies; or have not enrolled in long-term extension studies.
Exclusion Criteria
- No other subjects are eligible for this study
Data sourced from ClinicalTrials.gov (NCT01375127). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.